Investment Banking
An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.
Complete the form below to download your copy of the report
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Rapport Therapeutics, Inc., a clinical-stage leader in developing therapies targeting receptor-associated proteins focused on treating neurology and neuropsychiatry disorders of high unmet clinical need.
William Blair initiated research coverage of Neutron Holdings, Inc. (d/b/a Lime) (LIME $26.85), the world’s largest shared micromobility platform, operating fleets of e-scooters and e-bikes across roughly 230 cities and 29 countries through a vertically integrated model spanning proprietary hardware, data-driven operations, and scaled government relationships.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
